American Medical Association Establishes Category III CPT Code for Procedure Associated with the Use of MuReva Phototherapy’s LED-based Photobiomodulation Therapy Device
MuReva Phototherapy Presents Data during 2025 ASTRO Meeting Confirming Safety and Efficacy of the Company’s LED-based Photobiomodulation Therapy Device
MuReva Phototherapy presents data from pilot study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation (PBM) Device during the ASTRO 2023 Annual Meeting
MuReva Phototherapy presents data from pilot study of company’s photobiomodulation device during 2023 MASCC Annual Meeting
MuReva Phototherapy gains investment from the Angel Physicians Fund and adds Manish Bhandari, MD, E-MBA to Board of Directors
MuReva Phototherapy Awarded 1st Place at KJK New Venture Pitch contest during Cleveland Smart Business Dealmakers Conference
